menu

Loading...

CMND Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

1.245

Open

1.140

VWAP

1.20

Vol

63.73K

Mkt Cap

2.19M

Low

1.120

Amount

76.15K

EV/EBITDA(TTM)

--

Total Shares

1.79M

EV

-2.11M

EV/OCF(TTM)

--

P/S(TTM)

--

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

Show More

Events Timeline

(ET)

2026-02-17

16:50:00

Clearmind Medicine Files to Sell 8.17M Common Shares

2026-02-09 (ET)

2026-02-09

08:30:00

Clearmind Medicine Reports Safety Results for CMND-100 Clinical Trial

2026-02-06 (ET)

2026-02-06

08:00:00

Polyrizon Enters Development Agreement with Clearmind

2026-02-06

08:00:00

Clearmind Enters Development Agreement with Polyrizon

2026-02-03 (ET)

2026-02-03

08:20:00

Clearmind Medicine Welcomes Inclusion of MEAI in New Legislation

2026-01-14 (ET)

2026-01-14

09:10:00

Clearmind Medicine Completes Treatment for Second Cohort of CMND-100

News

PRnewswire

02-19PRnewswire

Clearmind's MEAI Drug Breakthrough in Obesity Treatment

Newsfilter

02-19Newsfilter

Clearmind's MEAI Drug Breakthrough in Obesity Treatment

NASDAQ.COM

02-09NASDAQ.COM

Clearmind Medicine Reports Positive Clinical Trial Results

Newsfilter

02-09Newsfilter

Clearmind Reports Positive Safety Results for AUD Drug in Phase I/IIa Trial

Yahoo Finance

02-08Yahoo Finance

Cannabis Sector Update: Aurora's Strategic Shift Amid Record Medical Sales

Globenewswire

2025-12-31Globenewswire

Clearmind Regains Nasdaq Compliance with Share Price Above $1

Valuation Metrics

The current forward P/E ratio for Clearmind Medicine Inc (CMND.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Clearmind Medicine Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

0.00

Current PE

0.00

Overvalued PE

0.00

Undervalued PE

0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding CMND

Trading Trends

People Also Watch

Frequently Asked Questions

What is Clearmind Medicine Inc (CMND) stock price today?

The current price of CMND is 1.22 USD — it has increased 7.96

What is Clearmind Medicine Inc (CMND)'s business?

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Company’s intellectual portfolio consists of 19 patent families including 31 granted patents.

What is the price predicton of CMND Stock?

Wall Street analysts forecast CMND stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMND is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clearmind Medicine Inc (CMND)'s revenue for the last quarter?

Clearmind Medicine Inc revenue for the last quarter amounts to -1.46M USD, decreased -7.23

What is Clearmind Medicine Inc (CMND)'s earnings per share (EPS) for the last quarter?

Clearmind Medicine Inc. EPS for the last quarter amounts to -1285827.00 USD, increased 19.37

How many employees does Clearmind Medicine Inc (CMND). have?

Clearmind Medicine Inc (CMND) has 4 emplpoyees as of March 02 2026.

What is Clearmind Medicine Inc (CMND) market cap?

Today CMND has the market capitalization of 2.19M USD.